Hangzhou Tigermed Consulting Co (HKSE:03347) Future 3-5Y EPS without NRI Growth Rate : 20.90 (As of May. 23, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate is 20.90.

Competitive Comparison of Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Hangzhou Tigermed Consulting Co (HKSE:03347) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Hangzhou Tigermed Consulting Co Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

5HZ1:Germany 300347:China

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Executives

Sands Capital Management, Llc	2101 Beneficial owner
Sands Capital Management, Lp	2201 Interest of corporation controlled by you
Sands Family Trust, Llc	2201 Interest of corporation controlled by you
Sands Frank Melville Jr.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
F-j Sands Family I, Llc	2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd	2102 Investment manager
Ninety One Uk Limited	2102 Investment manager
Baillie Gifford & Co	2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines